EXACT Sciences Co. (NASDAQ:EXAS) Shares Sold by Wisconsin Capital Management LLC
Wisconsin Capital Management LLC cut its position in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 35.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,125 shares of the medical research company’s stock after selling 14,600 shares during the period. EXACT Sciences makes up about 2.1% of Wisconsin Capital Management LLC’s portfolio, making the stock its 25th biggest holding. Wisconsin Capital Management LLC’s holdings in EXACT Sciences were worth $2,350,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in EXAS. First Hawaiian Bank grew its position in EXACT Sciences by 160.0% in the 1st quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock worth $28,000 after purchasing an additional 200 shares during the last quarter. Buffington Mohr McNeal acquired a new stake in shares of EXACT Sciences in the 1st quarter worth approximately $30,000. Mosaic Family Wealth LLC acquired a new stake in EXACT Sciences during the first quarter valued at approximately $37,000. Shine Investment Advisory Services Inc. lifted its stake in EXACT Sciences by 130.2% during the first quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 250 shares during the last quarter. Finally, Harvest Group Wealth Management LLC acquired a new stake in EXACT Sciences during the first quarter valued at approximately $39,000. 86.34% of the stock is owned by institutional investors.
Several equities research analysts recently commented on the stock. BidaskClub downgraded shares of EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 11th. Canaccord Genuity increased their price target on shares of EXACT Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Craig Hallum reiterated a “buy” rating and issued a $115.00 target price (up from $95.00) on shares of EXACT Sciences in a research note on Wednesday, May 1st. Zacks Investment Research upgraded shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, BTIG Research increased their price target on shares of EXACT Sciences to $130.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. EXACT Sciences presently has a consensus rating of “Buy” and an average price target of $108.45.
EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.01). The business had revenue of $162.00 million during the quarter, compared to the consensus estimate of $153.07 million. EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The company’s revenue was up 79.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.33) EPS. As a group, research analysts forecast that EXACT Sciences Co. will post -2.21 earnings per share for the current year.
In other news, insider Mark Stenhouse sold 11,192 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $92.54, for a total value of $1,035,707.68. Following the completion of the transaction, the insider now owns 25,500 shares of the company’s stock, valued at $2,359,770. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.20% of the company’s stock.
EXACT Sciences Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Recommended Story: Dividend Aristocrat Index
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.